Mereo BioPharma Group, a UK-based specialty biopharma company, has completed patient enrolment for a phase 2b clinical trial of BPS-804 (Setrusumab) intended for the treatment of osteogenesis imperfect (OI), it was reported yesterday.
The product has received Orphan Drug Designation from both the US Food and Drug Administration (FDA) and the European Medicines Agency for the product for OI, a form of brittle bone disease.
The investigational OI drug has also been accepted into the European Medicines Agency's Adaptive Pathways Program and was offered PRIority MEdicines (PRIME) designation.
The trial is a multi-centre, randomised, double-blind, dose-finding phase 2b study named ASTEROID and will assess the drug in a total of 112 adult patients across the United States and Europe, according to the company.
US FDA grants Orphan Drug Designation to AstraZeneca's saracatinib for idiopathic pulmonary fibrosis
AstraZeneca granted ODD to saracatinib for IPF by US FDA
Via Surgical awarded US FDA clearance for FasTouch Absorbable Fixation System
Perrigo wins US FDA tentative approval for generic Finacea Foam, 15%
Spectrum Pharmaceuticals Provides BLA Filing Update for Rolontis
Regulus reports departure of chief R&D officer Timothy Wright